Robert A. Lucas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert A. Lucas has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
B. Blake Weathersby
Department of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee
1 shared publicationJ. Michael Pepper
Department of Pharmacy, Saint Thomas Hospital, Nashville, Tennessee
1 shared publicationKerry L. Butler
Department of Pharmacy, Saint Thomas Hospital, Nashville, Tennessee
1 shared publicationVito K. Rocco
Division of Nephrology, Saint Thomas Hospital, Nashville, Tennessee
1 shared publication
Latest Publications
- 1 June 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (6) , 771-774
Rhabdomyolysis Associated with Cerivastatin: Six Cases within 3 Months at One Hospital
Rhabdomyolysis is an uncommon complication associated with 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors. We observed six cases of cerivastatin‐associated rhabdomyolysis: two patients developed acute renal failure requiring hemodialysis, and one patient died. Four of the patients had impaired renal function, and five were prescribed drugs with the potential to interact with cerivastatin. Also, five of the six patients presented with symptoms of rhabdomyolysis 3–4 weeks after starting cerivastatin therapy.
- 1 June 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (6) , 771-774
Rhabdomyolysis Associated with Cerivastatin: Six Cases within 3 Months at One Hospital
Rhabdomyolysis is an uncommon complication associated with 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors. We observed six cases of cerivastatin‐associated rhabdomyolysis: two patients developed acute renal failure requiring hemodialysis, and one patient died. Four of the patients had impaired renal function, and five were prescribed drugs with the potential to interact with cerivastatin. Also, five of the six patients presented with symptoms of rhabdomyolysis 3–4 weeks after starting cerivastatin therapy.